Dated: March 1, 1996. Susan K. Feldman, Committee Management Officer, NIH. [FR Doc. 96–5446 Filed 3–7–96; 8:45 am] BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the following Heart, Lung, and Blood Special Emphasis Panel.

This meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as signed language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: Pediatric Hydroxyurea Phase III Clinical Trial.

Dates of Meeting: April 12, 1996. Time of Meeting: 10:00 a.m.

Place of Meeting: National Institutes of Health, Two Rockledge Center, Room 9A2, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Agenda: To review Phase III Pediatric Hydroxyurea in Sickle Cell Anemia Trial.

Contact Person: Duane R. Bonds, M.D., Rockledge II Building, Rm. 10158, 6701 Rockledge Drive, Bethesda, Maryland 20892– 7950, (301) 435–0055.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 5, 1996.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 96–5509 Filed 3–7–96; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Heart, Lung, and Blood Program Project Review Committee, National Heart, Lung, and Blood Institute, March 20–21, 1996, 8:00 a.m., Holiday Inn Chevy Chase, Chevy Chase, Maryland, which was published in the Federal Register on February 1, 1996 (61 FR 3719).

The meeting date is changed to March 21–22, 1996. As previously advertised, the meeting is closed to the public.

Dated: March 5, 1996.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 96–5510 Filed 3–7–96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: March 6, 1996.

Time: 11 a.m.

Place: Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis L. Zusman, Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857; Telephone: 301, 443–1340.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing imitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281)

Dated: March 1, 1996. Susan K. Feldman.

Committee Management Officer, NIH. [FR Doc. 96–5508 Filed 3–5–96; 11:32 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: March 21, 1996.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4206, Telephone Conference.

Contact Person: Dr. Betty Hayden, Scientific Review Administrator, 6701 Rockledge Drive, Room 4206, Bethesda, Maryland 20892, (301) 435–1223.

Name of SEP: Biological and Physiological Sciences.

Date: March 22, 1996.

Time: 4:00 p.m.

Place: NIH, Rockledge 2, Room 4206, Telephone Conference.

Contact Person: Dr. Betty Hayden, Scientific Review Administrator, 6701 Rockledge Drive, Room 4206, Bethesda, Maryland 20892, (301) 435–1223.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 25, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4178, Telephone Conference.

Contact Person: Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4178, Bethesda, Maryland 20892, (301) 435–1146.

Name of SEP: Biological and Physiological Sciences.

Date: March 27, 1996.

Time: 8:30 a.m.

Place: NIH, Rockledge 2, Room 3163. Contact Person: Dr. Mushtaq Khan, Scientific Review Administrator, 6701 Rockledge Drive, Room 4124, Bethesda, Maryland 20892, (301) 435–1778.

Name of SEP: Clinical Sciences.

Date: March 29, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4112, Telephone Conference.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435–1783.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 3, 1996.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 4178, Telephone Conference.

Contact Person: Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4178, Bethesda, Maryland 20892, (301) 435–1146.

Name of SEP: Clinical Sciences.

Date: April 4, 1996.

Time: 8:00 a.m.

Place: Holiday Inn-Chevy Chase, Chevy Chase, MD.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435–1783.

Name of SEP: Clinical Sciences.

Date: April 4, 1996.

Time: 4:00 p.m.

Place: NIH, Rockledge 2, Room 4126, Telephone Conference.

Contact Person: Dr. Jerrold Fried, Scientific Review Administrator, 6701 Rockledge Drive, Room 4126, Bethesda, Maryland 20892, (301) 435–1777.

Purpose/Agenda: To review Small Business Innovation Research.

Name of SEP: Clinical Sciences.

Date: March 27, 1996.

Time: 8:00 a.m.

Place: Holiday Inn-Chevy Chase, Chevy Chase, MD.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435–1783.

Name of SEP: Biological and Physiological Sciences.

Date: April 8, 1996.

Time: 9:00 a.m.

Place: DoubleTree Hotel, Rockville, MD. Contact Person: Dr. Peggy McCardle, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435–1258.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 1, 1996. Susan K. Feldman, Committee Management Officer, NIH. [FR Doc. 96–5447 Filed 3–7–96; 8:45 am] BILLING CODE 4140–01–M

Technology Assessment Conference on Management of Temporomandibular Disorders

Notice is hereby given of the NIH Technology Assessment Conference on "Management of Temporomandibular Disorders," which will be held April 29-May 1, 1996, in the Natcher Conference Center of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference begins at 8:30 a.m. on April 29, at 8 a.m. on April 30, at 9 a.m. on May 1.

Temporomandibular disorders (TMD), a group of often painful conditions that affect the temporomandibular joint and muscles of mastication, confound and frustrate both patient and practitioner alike. Controversy surrounds virtually all aspects of TMD, from diagnosis and treatment to epidemiology and pathogenesis.

Even agreement on which conditions comprise temporomandibular disorders has been elusive. The term has been used to characterize individuals with a wide variety of symptoms and signs, such as pain in the face or jaw joint areas, headaches, earaches and dizziness, and clicking sounds in the jaw joint. A key issue to explore is the appropriateness of the label "TMD" for the numerous conditions now included under this rubric.

In the absence of universally accepted, scientifically based guidelines for diagnosing and managing temporomandibular disorders, diagnostic and treatment approaches of unproven value have proliferated in clinical practice. Concerns about their

safety and efficacy, as well as potential for harm, have arisen among clinicians and patients. There is a need to examine the rationale for and outcomes of a variety of treatments currently used in practice, such as behavioral and pharmacologic management, orthotics, surgery, occlusal therapy, orthodontics, physical therapy and others.

This conference will bring together specialists in pain management, cellular and molecular biology, epidemiology, immunology, behavioral and social sciences, tissue engineering, and clinical dentistry, medicine and surgery, as well as representatives from the public.

Time has been set aside from the scientific agenda in order to allow presentations by representatives of interested organizations. These presentations should address policy issues and may be up to 5 minutes in duration. Presentation by individuals representing personal views may be permitted if time allows, Requests to testify must be received by April 12, 1996 and should be sent to Jerry Elliott, Federal Building, Room 6C02, Bethesda, Maryland 20892, phone (301) 496–1144.

After 1½ days of presentations and audience discussion, an independent, non-Federal technology assessment panel will weigh the scientific evidence and write a draft statement that it will present to the audience on the third day. The technology assessment statement will address the following key questions:

- —What clinical conditions are classified as temporomandibular disorders, and what occurs if these conditions are left untreated?
- —What types of symptoms, signs, and other assessments provide a basis for initiating therapeutic interventions?
- —What are effective approaches to initial management and treatment of patients with various TMD subtypes?
- —What are effective approaches to management and treatment of patients with persistent TMD pain and dysfunction?
- —What are the most productive directions for future research, and what types of new collaborations and partnerships should be developed for pursuing these directions?

The primary sponsors of this conferences are the National Institute of Dental Research and the NIH Office of Medical Applications of Research. The conference is cosponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute of Neurological

Disorders and Stroke, the National Institute of Nursing Research, and the Office of Research on Women's Health.

Advance information on the conference program and conference registration materials may be obtained from: Laura Hazan, Technical Resources International, Inc., 3202 Tower Oaks Blvd., Suite 200, Rockville, Maryland 20852, (301) 770–31-53, confdept@techres.com.

The technology assessment statement will be submitted for publication in professional journals and other publications. In addition, the statement will be available beginning May 1, 1996, from the NIH Consensus Program Information Service, P.O. Box 2577, Kensington, Maryland 20891, phone 1–800–NIH–OMAR (1–800–644–6627).

Dated: February 20, 1996.

Ruth L. Kirschstein, Deputy Director, NIH.

[FR Doc. 96-5449 Filed 3-7-96; 8:45 am]

BILLING CODE 4140-01-M

HARRY S. TRUMAN SCHOLARSHIP FOUNDATION

Harry S. Truman Scholarship 1995 Supplemental Competition

AGENCY: Harry S. Truman Scholarship Foundation.

ACTION: Notice of closing date for supplemental nominations from eligible institutions of higher education.

SUMMARY: Notice is hereby given that, pursuant to the authority contained in the Harry S. Truman Memorial Scholarship Act, Public Law 93–642 (20 U.S.C. 2001), nominations are being accepted from eligible institutions of higher education for 1995 Truman Scholarships. Procedures are prescribed in 45 CFR 1801 (August 22, 1994; vol. 59, no. 161. sec. 13).

In order to be assured consideration, all documentation in support of nominations for the supplemental competition must be received by the Truman Scholarship Review Committee, 2255 N. Dubuque Road, P.O. Box 168, Iowa City, IA 52243 no later than March 29, 1996, from participating two- and four-year institutions.

Dated: February 12, 1996.

Louis H. Blair,

Executive Secretary.

[FR Doc. 96–5480 Filed 3–7–96; 8:45 am]

BILLING CODE 4738-10-M